Medicare enrollees who spend the most on prescription drugs will face a higher ceiling next year. The Centers for Medicare and Medicaid Services set the 2027 annual out-of-pocket spending cap for Part D at $2,400, a $300 increase from the $2,100 threshold in effect for 2026. The jump reflects a formula baked into federal law that ties the cap to rising per-capita drug costs, and it raises a pointed question: will the annual increases keep accelerating now that the Inflation Reduction Act has reshaped how Part D spending flows through the benefit structure?
Why the $300 jump from $2,100 to $2,400 hits enrollees now
Before 2025, Medicare Part D had no hard dollar limit on what beneficiaries paid out of pocket. The Inflation Reduction Act introduced a cap starting at $2,000 for 2025, then allowed it to rise each year based on the annual percentage increase in average per-capita aggregate expenditures for Part D covered drugs. CMS confirmed the 2026 threshold at $2,100 in its public-facing materials on Part D costs, and the agency’s calendar-year 2027 rate announcement established the next step at $2,400. That $300 year-over-year increase is a 14.3 percent rise, far steeper in percentage terms than the $100 move from 2025 to 2026.
The acceleration traces back to how the law restructured Part D benefits. Eliminating the old coverage gap, sometimes called the “donut hole,” pushed a larger share of total drug spending into the catastrophic phase, where plans and the federal government pick up nearly all costs. Because the statutory formula in Section 1395w-102 measures per-capita cost growth across the entire Part D program, concentrating more dollars in the catastrophic tier can inflate the growth rate that drives future cap adjustments. The practical result: the cap climbs faster in dollar terms than many enrollees expected when the $2,000 starting point was announced.
For beneficiaries with relatively modest prescription needs, the higher ceiling may never come into play. Many enrollees will continue to pay far less than $2,400 in a year, especially if they primarily use generics or have only a handful of maintenance medications. But for people with cancer, autoimmune conditions, or other illnesses treated with high-cost specialty drugs, the cap determines how much of their household budget is exposed to out-of-pocket spending. A $300 jump in the ceiling means that, in 2027, those patients could be asked to shoulder an additional $300 before their plan and Medicare pick up the rest.
CMS documents and the statutory formula behind the 2027 cap
CMS laid out the 2027 parameters across several official releases. In its comprehensive rate announcement for Medicare Advantage and Part D, the agency detailed payment policies and benefit thresholds for the coming plan year, including the updated out-of-pocket maximum. The same document described how the updated benefit design interacts with plan bids, reinsurance payments, and federal subsidies, underscoring that the cap is one of several levers shaping overall Part D spending.
A separate program-site notice on cost thresholds and cost limits for 2027 pointed directly to the PDF containing the updated parameters, giving employers and union retiree drug subsidy sponsors a second, independent confirmation of the new figures. Those sponsors rely on the same underlying Part D cost trends that drive the cap, so CMS’s alignment across documents signals that the $2,400 limit is firmly anchored in the statutory methodology rather than discretionary policy.
The statutory framework, codified in federal law, specifies that the cap increases each year in line with the percentage change in average per-capita aggregate Part D drug expenditures. CMS calculates that growth rate using program-wide data on covered drugs, including spending in the catastrophic phase. Because the Inflation Reduction Act shifted more liability for high-cost drugs onto plans and Medicare while capping beneficiary exposure, total program spending in later phases can rise even as individual patients see more predictable monthly bills. That tension is now surfacing in the form of larger annual adjustments to the cap.
What the higher cap means for beneficiaries and plans
For beneficiaries, the new ceiling represents both protection and exposure. On one hand, having any cap at all is a significant improvement over the pre-2025 design, when some patients faced effectively unlimited out-of-pocket costs. On the other hand, the $2,400 figure illustrates that the protection is not static. If drug prices and utilization continue to rise, the formula will allow the cap to ratchet higher, potentially outpacing Social Security benefit growth or other income sources that older adults rely on.
Part D plans must also adapt to the higher cap. As more spending shifts above the threshold where beneficiaries pay nothing, plans and Medicare shoulder a greater share of each additional dollar of drug cost. That dynamic can influence premiums, formulary design, and utilization management tools such as prior authorization or step therapy. Plans may respond by tightening coverage for some high-cost therapies or by steering enrollees toward lower-cost alternatives when clinically appropriate.
Looking ahead, policymakers and advocates are likely to watch closely how quickly the cap moves in subsequent years. The $300 jump between 2026 and 2027 is an early test of whether the Inflation Reduction Act’s restructuring will produce a pattern of steeper increases, or whether this year’s adjustment reflects a one-time recalibration as the new benefit design takes hold. For now, beneficiaries who routinely hit the cap should plan for higher maximum out-of-pocket costs in 2027, while recognizing that the ceiling still offers a clearer and more predictable limit than the open-ended exposure they faced just a few years ago.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
